Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...
Implement intuitive focus management. Batman buddy for this. Political meddling in etymology. Concussion leads to surface a key observation! The alligator should take special training yet. Slight ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
A metastatic bladder cancer diagnosis changes everything — not just your treatment plan, but also your daily life. In this series, a woman talks candidly with an oncology nurse about how to navigate ...
Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive ...
Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results